Preparing for change

What is the Unified Patent Court?

The UPC is a new common patents court with exclusive jurisdiction in respect of litigation (validity and infringement) for all EP(UPs) and non-exclusive jurisdiction over EPs validated in R-MS.

Currently, when granted by the European Patent Office, a European patent (EP) becomes a bundle of national rights that are validated and maintained in countries of commercial importance to your business.

Now the UPC is live, it has jurisdiction over all existing European patents (and related SPCs) in the R-MS. The UPC will be competent to hear:

  • Infringement & related defences and licences
  • Declarations of non-infringement
  • Protective Measures / Injunctions
  • Damages
  • Revocation and counterclaims for revocation
  • Compensation for licence of right

This means that the UPC can grant powerful pan-UPC injunctions, but equally can revoke the patents centrally across the R-MS and grant pan-UPC declarations of non-infringement. The UPC Rules envisage a judgment on the merits being provided within 1 year of a claim being issued.

This is a significant change to the current system, where enforcement and revocation of each of the national designations of the EP are litigated separately in the national patent courts.

The UPC is a supranational court (see below) made up of a network of local, regional and central patents divisions that will be located across the R-MS territories. The Court has a new set of rules and procedures that take features and tools of the existing EPC national patents courts. Most courts have indicated that English can be used as one of the possible languages and central division will use the language of the patent.

The UPC Central Divisions (currently Paris and Munich) deal with revocation and declarations of non-infringement proceedings. Local/regional courts deal with infringement, including preliminary injunctions. Arbitration is also available within the UPC. The Court of Appeal will be in Luxembourg and the courts will be able to make referrals to the Court of Justice of the European Union.

The procedure is front-loaded and there is an emphasis on written rather than oral advocacy. Injunctions, seizures, disclosure, expert evidence and cross-examination can be ordered by the Court. Potential infringers can lodge protective letters. There will be short interim hearings leading up to 1-2 day trials and a decision within 6 weeks of a final hearing.

There is costs shifting, with the loser paying the winning party’s costs but recovery of costs are capped relative to the value of the claim.

All EPs, including EP(UPs), remain subject to the same 9-month, post-grant opposition procedures. The existing EPO opposition rules continue to apply. Ongoing oppositions will have no effect on an opt-out from the UPC. Opposition proceedings can run in parallel with UPC proceedings but the UPC does have discretion to stay proceedings where a rapid decision is expected from the EPO.

The Unitary Patent

Pros and cons of opting-out?

Deciding on European patent opt-out varies for each company. Industries differ in their approaches based on litigiousness, risk appetite, and investment in establishing ownership.

What is a UP?

The prosecution of European Patents will continue as before. At grant a European Patent (“EP”) will create a bundle of national rights but a new UP “designation” will become available.

Preparing for change

On 1 June 2023, The Unified Patent Court (UPC) and a new “unitary patent” or “European patent with unitary effect” (UP) became a reality.

How do I opt-out of the UPC?

When the UPC comes into force, all existing and future European patents that are granted and validated in R-MS territories will become subject to the jurisdiction of the court.

Latest updates

Event - 27th October 2026

HGF sponsors pro-manchester Retail Lunch 2026

HGF is delighted to be sponsoring pro-manchester Retail Lunch 2026, taking place on Tuesday 27 October 2026 at INNSiDE by Meliá in Manchester. As part of the event, HGF Partner …

Event details
HGF

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article
HGF

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article
Event - 12th November 2026

HGF Partners with PPTI for 'Designing Foods for Healthy Aging' Webinar

As healthy aging, metabolic health and weight management rise up the consumer agenda, food and nutrition businesses are increasingly looking beyond traditional product development and towards solutions that deliver measurable …

Event details

Basel Seminar: Seminar on the new EU Pharma Package and its implications for regulatory exclusivities in the EU

Venue – Der Teufelhof Basel, Switzerland We are pleased to invite you to our seminar on the new EU Pharma Package and its implications for regulatory exclusivities in the EU. …

Read article
Event - 28th October 2026

HGF Attending BMCS Antibody–Drug Conjugates 2026

HGF is pleased to announce that Dr Thomas Lonsdale, Patent Director, will be attending the BMCS Antibody–Drug Conjugates 2026 meeting, taking place on 19 November 2026 at GSK, Stevenage, UK. …

Event details

Hsu Min Chung Recognised in IAM Global Leaders 2027

HGF is delighted to announce that Partner, Hsu Min Chung, has been recognised in the IAM Global Leaders 2027 guide, a prestigious ranking that highlights some of the world’s leading …

Read article